CORT   $42.27  3.30% Market Closed After Close 42.5 0.54%

Corcept Therapeutics Inc
Last Events:

2024-01-02 The hottest instrument.

2023-09-29 The hottest instrument.

2023-08-09 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-06 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-08-05 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: entrance to the overbought zone.

2023-08-05 Trend Power changed from slow to strong.

2023-08-04 Trend pattern changed from нисходящий клин to расширяющаяся формация.


Current temperature: 6.93
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 65.40
Mean unverified/preliminary 65.40 / 65.40
Target Price Low / High 45.00 / 78.00
Median / STD DEV 67.00 / 12.46
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch None None None
ma20 None ActivelyBuy ActivelyBuy
ma50 None None None
ma100 ActivelyBuy ActivelyBuy None
Candlestick PatternSept. 19, 2024 Dark Clouds Cover - is a candlestick pattern whereby a black candlestick opens above a white candlesticks close and below its midpoint.Considered to be a bearish reversal pattern.
ISIN US2183521028
ceo Dr. Joseph K. Belanoff M.D.
Website https://www.corcept.com
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.